The Analytical Scientist / Issues / 2026 / January / GLP1 Analysis Riding the Wave of Peptide Innovation
Pharma and Biopharma Pharma and Biopharma Trends Liquid Chromatography

GLP-1 Analysis: Riding the Wave of Peptide Innovation

The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges. Here, we outline the hurdles these peptides present, explore methods for impurity profiling and structural characterization, and consider strategies to keep pace with this fast-moving field.

By Amanda M. Guiraldelli, Piotr Alvarez, Koen Sandra 01/26/2026 12 min read

Share

Clinical Scorecard: GLP-1 Analysis: Riding the Wave of Peptide Innovation

At a Glance

CategoryDetail
Condition
Key MechanismsGLP-1 receptor agonism promotes weight loss through appetite suppression and enhances cardiovascular health by improving glycemic control and reducing blood pressure.
Target Population
Care Setting

Key Highlights

  • Patient-centric approaches are essential for improving adherence and treatment outcomes.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider GLP-1 RAs for weight management and cardiovascular risk reduction in patients with a history of cardiovascular disease.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Individuals with type 2 diabetes and obesity.

        Emerging therapies include dual and triple agonists, enhancing treatment options.

        Clinical Best Practices

        • Educate patients on the benefits and potential side effects of new therapies to enhance adherence.

        References

        About the Author(s)

        Amanda M. Guiraldelli

        Senior Scientist at RIC group, Belgium

        More Articles by Amanda M. Guiraldelli

        Piotr Alvarez

        Senior Scientist, RIC group, Belgium

        More Articles by Piotr Alvarez

        Koen Sandra

        Koen Sandra is CEO, RIC, Kortrijk, Belgium.

        More Articles by Koen Sandra

        Recommended

        Related Content

        Loading the Molecular Dice
        Pharma and Biopharma
        Loading the Molecular Dice

        December 12, 2024

        2 min read

        How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

        CD-MS: To Megadalton and Beyond
        Pharma and Biopharma
        CD-MS: To Megadalton and Beyond

        October 1, 2024

        10 min read

        Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

        New NMR Technique Enables Direct Detection of Molecular Chirality
        Pharma and Biopharma
        New NMR Technique Enables Direct Detection of Molecular Chirality

        October 1, 2024

        1 min read

        Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

        Mass Spec Imaging Meets Proteomics
        Pharma and Biopharma
        Mass Spec Imaging Meets Proteomics

        October 2, 2024

        2 min read

        Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment